CHAIN’s innovative platform technology supports a product pipeline and broad range of clinical applications.


CHAIN focus on the identification of small molecules and metabolites produced by the gut microbiome which are implicated in a wide range of clinical indications including control of infection and inflammation as well as receptor and CNS signalling.


CHAIN’s first candidate is a potent anti-inflammatory ketone body. The metabolic pathway has been engineered into our Clostridium host strain, a non-pathogenic species naturally present in the human gut. Preclinical tests with the lead product, CHN-1, show a reduction of pro-inflammatory cytokines and stimulation of key anti-inflammatory cytokines implicated in Inflammatory Bowel Disease.